Abstract
Inflammatory bowel disease (IBD) has gained increasing attention from researchers in terms of its pathophysiology as a global disease with a growing incidence. Although the exact etiology of IBD is still unknown currently, various studies have made us realize that it is related to the dysbiosis of intestinal microbiota and the link between the two may not just be a simple causal relationship, but also a dynamic and complicated one. The intestinal microbiota has been confirmed to be closely related to the occurrence, development, and treatment of IBD. Therefore, this review focuses on the changes in the structure, function, and metabolites of intestinal bacteria, fungi, and viruses in influencing IBD, as well as various approaches to IBD treatment by changing disordered intestinal microbiota. Ultimately, more clinical studies will be needed to focus on the efficacy of intestinal microbiota-based treatments in IBD, because of the existence of both advantages and disadvantages.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- IBD:
-
Inflammatory bowel disease
- CD:
-
Crohn’s disease
- UC:
-
Ulcerative colitis
- HS:
-
Healthy subjects
- E. coli :
-
Escherichia coli
- AIEC:
-
Adherent-invasive E. coli
- IEC:
-
Intestinal epithelial cells
- Treg:
-
Regulatory T cells
- IELs:
-
Intraepithelial lymphocytes
- TGF-β:
-
Transforming growth factor-β
- IL-10:
-
Interleukin-10
- SCFAs:
-
Short-chain fatty acids
- Trp:
-
Tryptophan
- SBAs:
-
Secondary bile acids
- GPRs:
-
G protein-coupled receptors
- PBAs:
-
Primary bile acids
- BA:
-
Bile acids
- LCA:
-
Lithocholic acid
- EEN:
-
Exclusive enteral nutrition
- CDED+PEN:
-
CD Exclusion Diet with Partial Enteral Nutrition
- NGP:
-
Next generation of probiotics
- XOS:
-
Xylo-oligosaccharide
- LA-GOS:
-
Lupinus Albus GOS
- OF-IN:
-
Oligofructose-enriched inulin
- CTM:
-
Cranberry concentrate Type M
- FMT:
-
Fecal microbiota transplantation
- CDI:
-
Clostridium difficile infection
- h-FMT:
-
Heterologous fecal microbiological transplantation
- a-FMT:
-
Autologous fecal transplantation
References
Agus A, Planchais J, Sokol H (2018) Gut Microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe 23:716–724. https://doi.org/10.1016/j.chom.2018.05.003
Aldars-García L, Gisbert JP, Chaparro M (2021) Metabolomics insights into inflammatory bowel disease: a comprehensive review. Pharmaceuticals (basel). https://doi.org/10.3390/ph14111190
Arpaia N et al (2013) Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504:451–455. https://doi.org/10.1038/nature12726
Astó E, Méndez I, Audivert S, Farran-Codina A, Espadaler J (2019) The efficacy of probiotics, prebiotic inulin-type fructans, and synbiotics in human ulcerative colitis: a systematic review and meta-analysis. Nutrients. https://doi.org/10.3390/nu11020293
Atarashi K et al (2011) Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331:337–341. https://doi.org/10.1126/science.1198469
Atarashi K et al (2013) Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 500:232–236. https://doi.org/10.1038/nature12331
Bäckhed F et al (2012) Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. Cell Host Microbe 12:611–622. https://doi.org/10.1016/j.chom.2012.10.012
Barnich N, Darfeuille-Michaud A (2010) Abnormal CEACAM6 expression in Crohn disease patients favors gut colonization and inflammation by adherent-invasive E. coli. Virulence 1:281–282. https://doi.org/10.4161/viru.1.4.11510
Basson AR, Zhou Y, Seo B, Rodriguez-Palacios A, Cominelli F (2020) Autologous fecal microbiota transplantation for the treatment of inflammatory bowel disease. Transl Res 226:1–11. https://doi.org/10.1016/j.trsl.2020.05.008
Benjamin JL et al (2011) Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn’s disease. Gut 60:923–929. https://doi.org/10.1136/gut.2010.232025
Bibiloni R et al (2005) VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 100:1539–1546. https://doi.org/10.1111/j.1572-0241.2005.41794.x
Blandford LE, Johnston EL, Sanderson JD, Wade WG, Lax AJ (2019) Promoter orientation of the immunomodulatory Bacteroides fragilis capsular polysaccharide A (PSA) is off in individuals with inflammatory bowel disease (IBD). Gut Microbes 10:569–577. https://doi.org/10.1080/19490976.2018.1560755
Bollyky PL, Secor PR (2019) The innate sense of bacteriophages. Cell Host Microbe 25:177–179. https://doi.org/10.1016/j.chom.2019.01.020
Boudeau J, Glasser AL, Julien S, Colombel JF, Darfeuille-Michaud A (2003) Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn’s disease. Aliment Pharmacol Ther 18:45–56. https://doi.org/10.1046/j.1365-2036.2003.01638.x
Breitbart M et al (2003) Metagenomic analyses of an uncultured viral community from human feces. J Bacteriol 185:6220–6223. https://doi.org/10.1128/jb.185.20.6220-6223.2003
Brown EM et al (2019) Bacteroides-derived sphingolipids are critical for maintaining intestinal homeostasis and symbiosis. Cell Host Microbe 25:668-680.e667. https://doi.org/10.1016/j.chom.2019.04.002
Caio G et al (2021) Nutritional treatment in Crohn’s disease. Nutrients. https://doi.org/10.3390/nu13051628
Campbell C et al (2020) Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells. Nature 581:475–479. https://doi.org/10.1038/s41586-020-2193-0
Chehoud C et al (2015) Fungal signature in the gut microbiota of pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 21:1948–1956. https://doi.org/10.1097/mib.0000000000000454
Chen HT et al (2020) Fecal microbiota transplantation ameliorates active ulcerative colitis. Exp Ther Med 19:2650–2660. https://doi.org/10.3892/etm.2020.8512
Clavel T, Haller D (2007) Bacteria- and host-derived mechanisms to control intestinal epithelial cell homeostasis: implications for chronic inflammation. Inflamm Bowel Dis 13:1153–1164. https://doi.org/10.1002/ibd.20174
Clooney AG et al (2019) Whole-virome analysis sheds light on viral dark matter in inflammatory bowel disease. Cell Host Microbe 26:764-778.e765. https://doi.org/10.1016/j.chom.2019.10.009
Cong J, Zhou P, Zhang R (2022) Intestinal microbiota-derived short chain fatty acids in host health and disease. Nutrients. https://doi.org/10.3390/nu14091977
Coqueiro AY, Raizel R, Bonvini A, Tirapegui J, Rogero MM (2019) Probiotics for inflammatory bowel diseases: a promising adjuvant treatment. Int J Food Sci Nutr 70:20–29. https://doi.org/10.1080/09637486.2018.1477123
Cox SR et al (2020) Effects of low fodmap diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology 158:176-188.e177. https://doi.org/10.1053/j.gastro.2019.09.024
Darb Emamie A et al (2021) The effects of probiotics, prebiotics and synbiotics on the reduction of IBD complications, a periodic review during 2009–2020. J Appl Microbiol 130:1823–1838. https://doi.org/10.1111/jam.14907
de Groot PF, Frissen MN, de Clercq NC, Nieuwdorp M (2017) Fecal microbiota transplantation in metabolic syndrome: History, present and future. Gut Microbes 8:253–267. https://doi.org/10.1080/19490976.2017.1293224
De Preter V (2015) Metabolomics in the clinical diagnosis of inflammatory bowel disease. Dig Dis 33(Suppl 1):2–10. https://doi.org/10.1159/000437033
De Preter V et al (2013) Metabolic profiling of the impact of oligofructose-enriched inulin in Crohn’s disease patients: a double-blinded randomized controlled trial. Clin Transl Gastroenterol 4:e30. https://doi.org/10.1038/ctg.2012.24
Deehan EC, Walter J (2016) The fiber gap and the disappearing gut microbiome: implications for human nutrition. Trends Endocrinol Metab 27:239–242. https://doi.org/10.1016/j.tem.2016.03.001
Derikx LA, Dieleman LA, Hoentjen F (2016) Probiotics and prebiotics in ulcerative colitis. Best Pract Res Clin Gastroenterol 30:55–71. https://doi.org/10.1016/j.bpg.2016.02.005
Derrien M, Vaughan EE, Plugge CM, de Vos WM (2004) Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol 54:1469–1476. https://doi.org/10.1099/ijs.0.02873-0
Diederen K et al (2020) Exclusive enteral nutrition mediates gut microbial and metabolic changes that are associated with remission in children with Crohn’s disease. Sci Rep 10:18879. https://doi.org/10.1038/s41598-020-75306-z
D’Incà R et al (2011) Rectal administration of Lactobacillus casei DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis. Dig Dis Sci 56:1178–1187. https://doi.org/10.1007/s10620-010-1384-1
Dollive S et al (2013) Fungi of the murine gut: episodic variation and proliferation during antibiotic treatment. PLoS ONE 8:e71806. https://doi.org/10.1371/journal.pone.0071806
Dong LN, Wang M, Guo J, Wang JP (2019) Role of intestinal microbiota and metabolites in inflammatory bowel disease. Chin Med J (engl) 132:1610–1614. https://doi.org/10.1097/cm9.0000000000000290
Duboc H et al (2013) Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 62:531–539. https://doi.org/10.1136/gutjnl-2012-302578
Eriksson F et al (2009) Tumor-specific bacteriophages induce tumor destruction through activation of tumor-associated macrophages. J Immunol 182:3105–3111. https://doi.org/10.4049/jimmunol.0800224
Fang X et al (2021) Gastrointestinal surgery for inflammatory bowel disease persistently lowers microbiome and metabolome diversity. Inflamm Bowel Dis 27:603–616. https://doi.org/10.1093/ibd/izaa262
Fernandes MA et al (2019) Enteric virome and bacterial microbiota in children with ulcerative colitis and Crohn disease. J Pediatr Gastroenterol Nutr 68:30–36. https://doi.org/10.1097/mpg.0000000000002140
Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR (2007) Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 104:13780–13785. https://doi.org/10.1073/pnas.0706625104
Franzosa EA et al (2019) Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol 4:293–305. https://doi.org/10.1038/s41564-018-0306-4
Fuentes S et al (2008) Administration of Lactobacillus casei and Lactobacillus plantarum affects the diversity of murine intestinal lactobacilli, but not the overall bacterial community structure. Res Microbiol 159:237–243. https://doi.org/10.1016/j.resmic.2008.02.005
Furrie E et al (2005) Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 54:242–249. https://doi.org/10.1136/gut.2004.044834
Furusawa Y et al (2013) Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504:446–450. https://doi.org/10.1038/nature12721
Galtier M et al (2017) Bacteriophages targeting adherent invasive Escherichia coli strains as a promising new treatment for Crohn’s disease. J Crohns Colitis 11:840–847. https://doi.org/10.1093/ecco-jcc/jjw224
Ganji-Arjenaki M, Rafieian-Kopaei M (2018) Probiotics are a good choice in remission of inflammatory bowel diseases: a meta analysis and systematic review. J Cell Physiol 233:2091–2103. https://doi.org/10.1002/jcp.25911
Gasaly N, de Vos P, Hermoso MA (2021) Impact of bacterial metabolites on gut barrier function and host immunity: a focus on bacterial metabolism and its relevance for intestinal inflammation. Front Immunol 12:658354. https://doi.org/10.3389/fimmu.2021.658354
Gaudier E et al (2004) Butyrate specifically modulates MUC gene expression in intestinal epithelial goblet cells deprived of glucose. Am J Physiol Gastrointest Liver Physiol 287:G1168-1174. https://doi.org/10.1152/ajpgi.00219.2004
Gentile CL, Weir TL (2018) The gut microbiota at the intersection of diet and human health. Science 362:776–780. https://doi.org/10.1126/science.aau5812
Gibson GR, Probert HM, Loo JV, Rastall RA, Roberfroid MB (2004) Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr Res Rev 17:259–275. https://doi.org/10.1079/nrr200479
Gibson GR et al (2017) Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol 14:491–502. https://doi.org/10.1038/nrgastro.2017.75
Glassner KL, Abraham BP, Quigley EMM (2020) The microbiome and inflammatory bowel disease. J Allergy Clin Immunol 145:16–27. https://doi.org/10.1016/j.jaci.2019.11.003
Glymenaki M et al (2017) Compositional changes in the gut mucus microbiota precede the onset of colitis-induced inflammation. Inflamm Bowel Dis 23:912–922. https://doi.org/10.1097/mib.0000000000001118
Godínez-Méndez LA et al (2021) In vivo healthy benefits of galacto-oligosaccharides from Lupinus albus (LA-GOS) in butyrate production through intestinal microbiota. Biomolecules. https://doi.org/10.3390/biom11111658
Gogokhia L, Round JL (2021) Immune-bacteriophage interactions in inflammatory bowel diseases. Curr Opin Virol 49:30–35. https://doi.org/10.1016/j.coviro.2021.04.010
Guan Q (2019) A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res 2019:7247238. https://doi.org/10.1155/2019/7247238
Gupta A, Saha S, Khanna S (2020) Therapies to modulate gut microbiota: past, present and future. World J Gastroenterol 26:777–788. https://doi.org/10.3748/wjg.v26.i8.777
Halfvarson J et al (2017) Dynamics of the human gut microbiome in inflammatory bowel disease. Nat Microbiol 2:17004. https://doi.org/10.1038/nmicrobiol.2017.4
Hang S et al (2019) Bile acid metabolites control T(H)17 and T(reg) cell differentiation. Nature 576:143–148. https://doi.org/10.1038/s41586-019-1785-z
Hansen T, Duerksen DR (2018) Enteral nutrition in the management of pediatric and adult Crohn’s disease. Nutrients. https://doi.org/10.3390/nu10050537
Harris KG, Chang EB (2018) The intestinal microbiota in the pathogenesis of inflammatory bowel diseases: new insights into complex disease. Clin Sci (lond) 132:2013–2028. https://doi.org/10.1042/cs20171110
He L et al (2020) Stachyose modulates gut microbiota and alleviates dextran sulfate sodium-induced acute colitis in mice. Saudi J Gastroenterol 26:153–159. https://doi.org/10.4103/sjg.SJG_580_19
Holscher HD (2017) Dietary fiber and prebiotics and the gastrointestinal microbiota. Gut Microbes 8:172–184. https://doi.org/10.1080/19490976.2017.1290756
Hvas CL, Bendix M, Dige A, Dahlerup JF, Agnholt J (2018) Current, experimental, and future treatments in inflammatory bowel disease: a clinical review. Immunopharmacol Immunotoxicol 40:446–460. https://doi.org/10.1080/08923973.2018.1469144
Hyun CK (2021) Molecular and pathophysiological links between metabolic disorders and inflammatory bowel diseases. Int J Mol Sci. https://doi.org/10.3390/ijms22179139
Ianiro G, Tilg H, Gasbarrini A (2016) Antibiotics as deep modulators of gut microbiota: between good and evil. Gut 65:1906–1915. https://doi.org/10.1136/gutjnl-2016-312297
Iliev ID, Cadwell K (2021) Effects of intestinal fungi and viruses on immune responses and inflammatory bowel diseases. Gastroenterology 160:1050–1066. https://doi.org/10.1053/j.gastro.2020.06.100
Jakubczyk D, Leszczyńska K, Górska S (2020) The effectiveness of probiotics in the treatment of inflammatory bowel disease (IBD)—a critical review. Nutrients. https://doi.org/10.3390/nu12071973
Joossens M, De Preter V, Ballet V, Verbeke K, Rutgeerts P, Vermeire S (2012) Effect of oligofructose-enriched inulin (OF-IN) on bacterial composition and disease activity of patients with Crohn’s disease: results from a double-blinded randomised controlled trial. Gut 61:958. https://doi.org/10.1136/gutjnl-2011-300413
Khan I et al (2019) Alteration of gut microbiota in inflammatory bowel disease (IBD): cause or consequence? IBD treatment targeting the gut microbiome. Pathogens. https://doi.org/10.3390/pathogens8030126
Khoruts A, Sadowsky MJ (2016) Understanding the mechanisms of faecal microbiota transplantation. Nat Rev Gastroenterol Hepatol 13:508–516. https://doi.org/10.1038/nrgastro.2016.98
Kim MH, Kang SG, Park JH, Yanagisawa M, Kim CH (2013) Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. Gastroenterology 145:396–406. https://doi.org/10.1053/j.gastro.2013.04.056
Knox NC, Forbes JD, Peterson CL, Van Domselaar G, Bernstein CN (2019) The gut microbiome in inflammatory bowel disease: lessons learned from other immune-mediated inflammatory diseases. Am J Gastroenterol 114:1051–1070. https://doi.org/10.14309/ajg.0000000000000305
Koboziev I, Reinoso Webb C, Furr KL, Grisham MB (2014) Role of the enteric microbiota in intestinal homeostasis and inflammation. Free Radic Biol Med 68:122–133. https://doi.org/10.1016/j.freeradbiomed.2013.11.008
Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F (2016) From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell 165:1332–1345. https://doi.org/10.1016/j.cell.2016.05.041
Kong L et al (2020) Linking strain engraftment in fecal microbiota transplantation with maintenance of remission in Crohn’s disease. Gastroenterology 159:2193-2202.e2195. https://doi.org/10.1053/j.gastro.2020.08.045
Kruis W et al (2004) Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53:1617–1623. https://doi.org/10.1136/gut.2003.037747
Kump PK et al (2013) Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis 19:2155–2165. https://doi.org/10.1097/MIB.0b013e31829ea325
Larson DW, Pemberton JH (2004) Current concepts and controversies in surgery for IBD. Gastroenterology 126:1611–1619. https://doi.org/10.1053/j.gastro.2004.03.063
Lavelle A, Sokol H (2020) Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 17:223–237. https://doi.org/10.1038/s41575-019-0258-z
Ledder O, Turner D (2018) Antibiotics in IBD: still a role in the biological era? Inflamm Bowel Dis 24:1676–1688. https://doi.org/10.1093/ibd/izy067
Lee M, Chang EB (2021) Inflammatory bowel diseases (IBD) and the microbiome-searching the crime scene for clues. Gastroenterology 160:524–537. https://doi.org/10.1053/j.gastro.2020.09.056
Leonardi I et al (2020) Fungal trans-kingdom dynamics linked to responsiveness to fecal microbiota transplantation (FMT) therapy in ulcerative colitis. Cell Host Microbe 27:823-829.e823. https://doi.org/10.1016/j.chom.2020.03.006
Levine A et al (2019) Crohn’s disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology 157:440-450.e448. https://doi.org/10.1053/j.gastro.2019.04.021
Lewis JD et al (2015) Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn’s disease. Cell Host Microbe 18:489–500. https://doi.org/10.1016/j.chom.2015.09.008
Li Z et al (2021) Effects of xylo-oligosaccharide on the gut microbiota of patients with ulcerative colitis in clinical remission. Front Nutr 8:778542. https://doi.org/10.3389/fnut.2021.778542
Liang G et al (2020) Dynamics of the stool virome in very early-onset inflammatory bowel disease. J Crohns Colitis 14:1600–1610. https://doi.org/10.1093/ecco-jcc/jjaa094
Lichtenstein L, Avni-Biron I, Ben-Bassat O (2016) Probiotics and prebiotics in Crohn’s disease therapies. Best Pract Res Clin Gastroenterol 30:81–88. https://doi.org/10.1016/j.bpg.2016.02.002
Liguori G et al (2016) Fungal dysbiosis in mucosa-associated microbiota of Crohn’s disease patients. J Crohns Colitis 10:296–305. https://doi.org/10.1093/ecco-jcc/jjv209
Lindsay JO et al (2006) Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn’s disease. Gut 55:348–355. https://doi.org/10.1136/gut.2005.074971
Liu S, Zhao W, Lan P, Mou X (2021) The microbiome in inflammatory bowel diseases: from pathogenesis to therapy. Protein Cell 12:331–345. https://doi.org/10.1007/s13238-020-00745-3
Lloyd-Price J et al (2019) Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature 569:655–662. https://doi.org/10.1038/s41586-019-1237-9
Long SL, Gahan CGM, Joyce SA (2017) Interactions between gut bacteria and bile in health and disease. Mol Aspects Med 56:54–65. https://doi.org/10.1016/j.mam.2017.06.002
Loubinoux J, Bronowicki JP, Pereira IA, Mougenel JL, Faou AE (2002) Sulfate-reducing bacteria in human feces and their association with inflammatory bowel diseases. FEMS Microbiol Ecol 40:107–112. https://doi.org/10.1111/j.1574-6941.2002.tb00942.x
Łusiak-Szelachowska M, Weber-Dąbrowska B, Jończyk-Matysiak E, Wojciechowska R, Górski A (2017) Bacteriophages in the gastrointestinal tract and their implications. Gut Pathog 9:44. https://doi.org/10.1186/s13099-017-0196-7
Magnusson MK et al (2016) Anti-TNF therapy response in patients with ulcerative colitis is associated with colonic antimicrobial peptide expression and microbiota composition. J Crohns Colitis 10:943–952. https://doi.org/10.1093/ecco-jcc/jjw051
Manichanh C et al (2006) Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut 55:205–211. https://doi.org/10.1136/gut.2005.073817
Marchesi JR et al (2007) Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res 6:546–551. https://doi.org/10.1021/pr060470d
Markowiak P, Śliżewska K (2017) Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients. https://doi.org/10.3390/nu9091021
Martinez-Medina M, Garcia-Gil LJ (2014) Escherichia coli in chronic inflammatory bowel diseases: an update on adherent invasive Escherichia coli pathogenicity. World J Gastrointest Pathophysiol 5:213–227. https://doi.org/10.4291/wjgp.v5.i3.213
Martyniak A, Medyńska-Przęczek A, Wędrychowicz A, Skoczeń S, Tomasik PJ (2021) Prebiotics, probiotics, synbiotics, paraprobiotics and postbiotic compounds in IBD. Biomolecules. https://doi.org/10.3390/biom11121903
Mason KL et al (2012) Candida albicans and bacterial microbiota interactions in the cecum during recolonization following broad-spectrum antibiotic therapy. Infect Immun 80:3371–3380. https://doi.org/10.1128/iai.00449-12
Matijašić M et al (2016) Modulating composition and metabolic activity of the gut microbiota in IBD patients. Int J Mol Sci. https://doi.org/10.3390/ijms17040578
Matsuoka K et al (2018) Efficacy of bifidobacterium breve fermented milk in maintaining remission of ulcerative colitis. Dig Dis Sci 63:1910–1919. https://doi.org/10.1007/s10620-018-4946-2
Mentella MC, Scaldaferri F, Pizzoferrato M, Gasbarrini A, Miggiano GAD (2020) Nutrition, IBD and gut microbiota: a review. Nutrients. https://doi.org/10.3390/nu12040944
Minot S et al (2011) The human gut virome: inter-individual variation and dynamic response to diet. Genome Res 21:1616–1625. https://doi.org/10.1101/gr.122705.111
Mirsepasi-Lauridsen HC, Vallance BA, Krogfelt KA, Petersen AM (2019) Escherichia coli pathobionts associated with inflammatory bowel disease. Clin Microbiol Rev. https://doi.org/10.1128/cmr.00060-18
Morgan XC et al (2012) Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 13:R79. https://doi.org/10.1186/gb-2012-13-9-r79
Mousa WK, Chehadeh F, Husband S (2022) Recent advances in understanding the structure and function of the human microbiome. Front Microbiol 13:825338. https://doi.org/10.3389/fmicb.2022.825338
Newman KM, Rank KM, Vaughn BP, Khoruts A (2017) Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease. Gut Microbes 8:303–309. https://doi.org/10.1080/19490976.2017.1279377
Ni J, Wu GD, Albenberg L, Tomov VT (2017) Gut microbiota and IBD: causation or correlation? Nat Rev Gastroenterol Hepatol 14:573–584. https://doi.org/10.1038/nrgastro.2017.88
Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A (2018) Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol 11:1–10. https://doi.org/10.1007/s12328-017-0813-5
Nishiyama H, Endo H, Blanc-Mathieu R, Ogata H (2020) Ecological structuring of temperate bacteriophages in the inflammatory bowel disease-affected gut. Microorganisms. https://doi.org/10.3390/microorganisms8111663
Norman JM et al (2015) Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell 160:447–460. https://doi.org/10.1016/j.cell.2015.01.002
Noverr MC, Noggle RM, Toews GB, Huffnagle GB (2004) Role of antibiotics and fungal microbiota in driving pulmonary allergic responses. Infect Immun 72:4996–5003. https://doi.org/10.1128/iai.72.9.4996-5003.2004
Noverr MC, Falkowski NR, McDonald RA, McKenzie AN, Huffnagle GB (2005) Development of allergic airway disease in mice following antibiotic therapy and fungal microbiota increase: role of host genetics, antigen, and interleukin-13. Infect Immun 73:30–38. https://doi.org/10.1128/iai.73.1.30-38.2005
Oh WS, Jung JC, Choi YM, Mun JY, Ku SK, Song CH (2020) Protective effects of fermented rice extract on ulcerative colitis induced by dextran sodium sulfate in mice. Food Sci Nutr 8:1718–1728. https://doi.org/10.1002/fsn3.1460
Oka A, Sartor RB (2020) Microbial-based and microbial-targeted therapies for inflammatory bowel diseases. Dig Dis Sci 65:757–788. https://doi.org/10.1007/s10620-020-06090-z
Ooijevaar RE, Terveer EM, Verspaget HW, Kuijper EJ, Keller JJ (2019) Clinical application and potential of fecal microbiota transplantation. Annu Rev Med 70:335–351. https://doi.org/10.1146/annurev-med-111717-122956
Ossa JC, Ho NK, Wine E, Leung N, Gray-Owen SD, Sherman PM (2013) Adherent-invasive Escherichia coli blocks interferon-γ-induced signal transducer and activator of transcription (STAT)-1 in human intestinal epithelial cells. Cell Microbiol 15:446–457. https://doi.org/10.1111/cmi.12048
Ott SJ et al (2004) Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 53:685–693. https://doi.org/10.1136/gut.2003.025403
Palmela C et al (2018) Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut 67:574–587. https://doi.org/10.1136/gutjnl-2017-314903
Paramsothy S et al (2019) Specific bacteria and metabolites associated with response to fecal microbiota transplantation in patients with ulcerative colitis. Gastroenterology 156:1440-1454.e1442. https://doi.org/10.1053/j.gastro.2018.12.001
Peng L, Zhong Y, Wang A, Jiang Z (2019) Probiotics combined with aminosalicylic acid affiliates remission of ulcerative colitis: a meta-analysis of randomized controlled trial. Biosci Rep. https://doi.org/10.1042/bsr20180943
Peterson DA, Frank DN, Pace NR, Gordon JI (2008) Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe 3:417–427. https://doi.org/10.1016/j.chom.2008.05.001
Qiu X et al (2020) Characterization of fungal and bacterial dysbiosis in young adult Chinese patients with Crohn’s disease. Ther Adv Gastroenterol 13:1756284820971202. https://doi.org/10.1177/1756284820971202
Quraishi MN et al (2017) Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther 46:479–493. https://doi.org/10.1111/apt.14201
Qv L, Mao S, Li Y, Zhang J, Li L (2021) Roles of gut bacteriophages in the pathogenesis and treatment of inflammatory bowel disease. Front Cell Infect Microbiol 11:755650. https://doi.org/10.3389/fcimb.2021.755650
Radhakrishnan ST et al (2022) Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease. Aliment Pharmacol Ther 55:26–48. https://doi.org/10.1111/apt.16656
Reyes A et al (2010) Viruses in the faecal microbiota of monozygotic twins and their mothers. Nature 466:334–338. https://doi.org/10.1038/nature09199
Reyes A, Wu M, McNulty NP, Rohwer FL, Gordon JI (2013) Gnotobiotic mouse model of phage-bacterial host dynamics in the human gut. Proc Natl Acad Sci USA 110:20236–20241. https://doi.org/10.1073/pnas.1319470110
Ribaldone DG et al (2019) Adalimumab therapy improves intestinal dysbiosis in crohn’s disease. J Clin Med. https://doi.org/10.3390/jcm8101646
Rodríguez C et al (2020) Microbiota insights in clostridium difficile infection and inflammatory bowel disease. Gut Microbes 12:1725220. https://doi.org/10.1080/19490976.2020.1725220
Rolhion N et al (2010) Abnormally expressed ER stress response chaperone Gp96 in CD favours adherent-invasive Escherichia coli invasion. Gut 59:1355–1362. https://doi.org/10.1136/gut.2010.207456
Rothschild D et al (2018) Environment dominates over host genetics in shaping human gut microbiota. Nature 555:210–215. https://doi.org/10.1038/nature25973
Rowan F, Docherty NG, Murphy M, Murphy B, Calvin Coffey J, O’Connell PR (2010) Desulfovibrio bacterial species are increased in ulcerative colitis. Dis Colon Rectum 53:1530–1536. https://doi.org/10.1007/DCR.0b013e3181f1e620
Ruigrok R et al (2021) The composition and metabolic potential of the human small intestinal microbiota within the context of inflammatory bowel disease. J Crohns Colitis 15:1326–1338. https://doi.org/10.1093/ecco-jcc/jjab020
Saez A, Gomez-Bris R, Herrero-Fernandez B, Mingorance C, Rius C, Gonzalez-Granado JM (2021) Innate lymphoid cells in intestinal homeostasis and inflammatory bowel disease. Int J Mol Sci. https://doi.org/10.3390/ijms22147618
Sarrabayrouse G, Alameddine J, Altare F, Jotereau F (2015) Microbiota-specific CD4CD8αα tregs: role in intestinal immune homeostasis and implications for IBD. Front Immunol 6:522. https://doi.org/10.3389/fimmu.2015.00522
Sartor RB (2006) Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 3:390–407. https://doi.org/10.1038/ncpgasthep0528
Sartor RB (2008) Microbial influences in inflammatory bowel diseases. Gastroenterology 134:577–594. https://doi.org/10.1053/j.gastro.2007.11.059
Sartor RB, Wu GD (2017) Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology 152:327-339.e324. https://doi.org/10.1053/j.gastro.2016.10.012
Scanlan PD, Shanahan F, O’Mahony C, Marchesi JR (2006) Culture-independent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn’s disease. J Clin Microbiol 44:3980–3988. https://doi.org/10.1128/jcm.00312-06
Schirmer M, Garner A, Vlamakis H, Xavier RJ (2019) Microbial genes and pathways in inflammatory bowel disease. Nat Rev Microbiol 17:497–511. https://doi.org/10.1038/s41579-019-0213-6
Sokol H et al (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 105:16731–16736. https://doi.org/10.1073/pnas.0804812105
Sokol H et al (2017) Fungal microbiota dysbiosis in IBD. Gut 66:1039–1048. https://doi.org/10.1136/gutjnl-2015-310746
Somineni HK, Kugathasan S (2019) The microbiome in patients with inflammatory diseases. Clin Gastroenterol Hepatol 17:243–255. https://doi.org/10.1016/j.cgh.2018.08.078
Sonnenburg JL, Chen CT, Gordon JI (2006) Genomic and metabolic studies of the impact of probiotics on a model gut symbiont and host. PLoS Biol 4:e413. https://doi.org/10.1371/journal.pbio.0040413
Starz E et al (2021) The modification of the gut microbiota via selected specific diets in patients with Crohn’s disease. Nutrients. https://doi.org/10.3390/nu13072125
Steed H, Macfarlane GT, Macfarlane S (2008) Prebiotics, synbiotics and inflammatory bowel disease. Mol Nutr Food Res 52:898–905. https://doi.org/10.1002/mnfr.200700139
Steed H et al (2010) Clinical trial: the microbiological and immunological effects of synbiotic consumption—a randomized double-blind placebo-controlled study in active Crohn’s disease. Aliment Pharmacol Ther 32:872–883. https://doi.org/10.1111/j.1365-2036.2010.04417.x
Sun M, Wu W, Liu Z, Cong Y (2017) Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases. J Gastroenterol 52:1–8. https://doi.org/10.1007/s00535-016-1242-9
Suskind DL et al (2020) The specific carbohydrate diet and diet modification as induction therapy for pediatric crohn’s disease: a randomized diet controlled trial. Nutrients. https://doi.org/10.3390/nu12123749
Takahashi K et al (2016) Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in crohn’s disease. Digestion 93:59–65. https://doi.org/10.1159/000441768
Tap J et al (2015) Gut microbiota richness promotes its stability upon increased dietary fibre intake in healthy adults. Environ Microbiol 17:4954–4964. https://doi.org/10.1111/1462-2920.13006
Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:1027–1031. https://doi.org/10.1038/nature05414
Underhill DM, Iliev ID (2014) The mycobiota: interactions between commensal fungi and the host immune system. Nat Rev Immunol 14:405–416. https://doi.org/10.1038/nri3684
Ungaro F et al (2019) Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease. Gut Microbes 10:149–158. https://doi.org/10.1080/19490976.2018.1511664
Vaughn BP et al (2016) Increased intestinal microbial diversity following fecal microbiota transplant for active crohn’s disease. Inflamm Bowel Dis 22:2182–2190. https://doi.org/10.1097/mib.0000000000000893
Venkatesh M et al (2014) Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. Immunity 41:296–310. https://doi.org/10.1016/j.immuni.2014.06.014
Vich Vila A et al (2018) Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aap8914
Wallace KL, Zheng LB, Kanazawa Y, Shih DQ (2014) Immunopathology of inflammatory bowel disease. World J Gastroenterol 20:6–21. https://doi.org/10.3748/wjg.v20.i1.6
Wang Y, Guo Y, Chen H, Wei H, Wan C (2018) Potential of Lactobacillus plantarum ZDY2013 and Bifidobacterium bifidum WBIN03 in relieving colitis by gut microbiota, immune, and anti-oxidative stress. Can J Microbiol 64:327–337. https://doi.org/10.1139/cjm-2017-0716
Wark G, Samocha-Bonet D, Ghaly S, Danta M (2020) The role of diet in the pathogenesis and management of inflammatory bowel disease: a review. Nutrients. https://doi.org/10.3390/nu13010135
Weingarden AR et al (2014) Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol 306:G310-319. https://doi.org/10.1152/ajpgi.00282.2013
Wieërs G et al (2019) How probiotics affect the microbiota. Front Cell Infect Microbiol 9:454. https://doi.org/10.3389/fcimb.2019.00454
Williams BB et al (2014) Discovery and characterization of gut microbiota decarboxylases that can produce the neurotransmitter tryptamine. Cell Host Microbe 16:495–503. https://doi.org/10.1016/j.chom.2014.09.001
Yan JB, Luo MM, Chen ZY, He BH (2020) The Function and role of the Th17/Treg cell balance in inflammatory bowel disease. J Immunol Res 2020:8813558. https://doi.org/10.1155/2020/8813558
Yang Z et al (2020) Fecal microbiota transplant via endoscopic delivering through small intestine and colon: no difference for crohn’s disease. Dig Dis Sci 65:150–157. https://doi.org/10.1007/s10620-019-05751-y
Yang M et al (2021) Bile acid-gut microbiota axis in inflammatory bowel disease: from bench to bedside. Nutrients. https://doi.org/10.3390/nu13093143
Zelante T et al (2013) Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 39:372–385. https://doi.org/10.1016/j.immuni.2013.08.003
Zhang F, Luo W, Shi Y, Fan Z, Ji G (2012) Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol 107:1755. https://doi.org/10.1038/ajg.2012.251 (author reply pp. 1755–1756)
Zhang D et al (2021a) A cranberry concentrate decreases adhesion and invasion of Escherichia coli (AIEC) LF82 in vitro. Pathogens. https://doi.org/10.3390/pathogens10091217
Zhang S et al (2021b) The alterations in and the role of the Th17/Treg balance in metabolic diseases. Front Immunol 12:678355. https://doi.org/10.3389/fimmu.2021.678355
Zhou Y et al (2018) Gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction. mSystems. https://doi.org/10.1128/mSystems.00188-17
Zhou C, Qiu Y, Yang H (2019) CD4CD8αα IELs: they have something to say. Front Immunol 10:2269. https://doi.org/10.3389/fimmu.2019.02269
Zuo T et al (2019) Gut mucosal virome alterations in ulcerative colitis. Gut 68:1169–1179. https://doi.org/10.1136/gutjnl-2018-318131
Funding
This study was supported by CNS-ZD Tizhi and Health Fund (CNS-ZD2020-21) and Key Research and Development Project of Hubei Province (2020BCA081-03).
Author information
Authors and Affiliations
Contributions
All the authors contributed to this review. The first draft of the manuscript was written by Qianyu Li and all the authors reviewed and edited on previous versions of the manuscript. All the authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors have no relevant financial or non-financial interests to disclose.
Additional information
Communicated by Erko Stackebrandt.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Li, Q., Zhou, S., Wang, Y. et al. Changes of intestinal microbiota and microbiota-based treatments in IBD. Arch Microbiol 204, 442 (2022). https://doi.org/10.1007/s00203-022-03069-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00203-022-03069-4